

Synthesis of Pyrano[4,3-*c*]pyrazol-4(1*H*)-ones and -4(2*H*)-ones from Dehydroacetic Acid. Homo- and Heteronuclear Selective NOE Measurements for Unambiguous Structure Assignment

Albert CANTOS, Pedro de MARCH, Marcial MORENO-MAÑAS,* Anna PLA, FRANCISCO SANCHEZ-FERRANDO,* and Albert VIRGILI


Departament de Química. Universitat Autònoma de Barcelona, Campus de Bellaterra, 08193 Barcelona, Spain
(Received October 20, 1986)

Cyclization of dehydroacetic acid *N*-substituted hydrazones furnished 1-substituted 3,6-dimethylpyrano[4,3-*c*]pyrazol-4(1*H*)-ones, together with varying amounts of *N,N'*-disubstituted 5-hydroxy-3-methyl-4-(3-methyl-1*H*-pyrazol-5-yl)-1*H*-pyrazoles. The same pyranopyrazolones were obtained regioselectively without side reactions from *N*-alkylhydrazines and 4-chloro-3-(1-chlorovinyl)-6-methyl-2*H*-pyran-2-one, ("Dehydroacetchlorid"), while *N*-arylhydrazines gave the 2-aryl-3,6-dimethylpyrano[4,3-*c*]pyrazol-4(2*H*)-ones. NMR NOE methods, including long-range selective heteronuclear $^{13}\text{C}\{^1\text{H}\}$ NOE enhancement measurements, allowed unambiguous distinction between -4(1*H*)-ones and -4(2*H*)-ones.

The reactions of dehydroacetic acid **1** and derivatives with hydroxylamine or hydrazines are a rich source of several types of heterocycles¹⁾ (Scheme 1). Thus, the initially formed oxime **2** or hydrazones **3** have been converted into 3,6-dimethyl-4*H*-pyrano[3,4-*d*]isoxazol-4-one (**4**)²⁾ or into pyrano[4,3-*c*]pyrazol-4(1*H*)-ones (**5**)³⁾, 4-acetoacetyl-2,4-dihydro-5-methyl-3*H*-pyrazol-3-ones (**6**)⁴⁾, 2,4-dihydro-5-methyl-3*H*-pyrazol-3-ones (**7**)⁵⁾ or their formal condensation dimers 5-hydroxy-3-methyl-4-(3-methyl-1*H*-pyrazol-5-yl)-1*H*-pyrazoles (**8**)^{3,4)}, pyrano[2,3-*c*]pyrazol-4(1*H*)-ones (**9**)⁴⁾ and 5-(2-oxopropyl)-1*H*-pyrazole-4-carboxylates (**10**)^{3b,c)}. 4-(5-Isoxazolyl)isoxazole (**11**) has also been reported⁶⁾ from reaction of **1** with hydroxylamine. Even the formation of 5-anilino-1,5-dihydro-3,6-dimethyl-1-phenyl-4*H*-pyrazolo[4,3-*c*]pyridin-4-one from **1** and phenylhydrazine was once claimed,⁷⁾ although this reaction was later shown⁴⁾ to afford only **8b**. Depending upon the reaction conditions, most compounds **5**–**10** can be

obtained directly from **1** and hydrazines, usually as mixtures with the corresponding hydrazones **3**.^{3c)} Furthermore, reaction of the methyl ether of dehydroacetic acid (**12**) with phenylhydrazine or hydroxylamine gives 3,6-dimethyl-2-phenylpyrano[4,3-*c*]pyrazol-4(2*H*)-one (**13b**)^{3c,8)} or 3,6-dimethyl-4*H*-pyrano[4,3-*c*]isoxazol-4-one (**14**)^{3c,8)} while Oppenheim's "Dehydroacetchlorid,"⁹⁾ of hitherto-unknown constitution, has long been known^{9b)} to react with phenylhydrazine giving an as yet unidentified isomer, mp 203 °C, of **5b**.

Clearly, some sort of control on regioselectivity is desirable for this manifold of reactions and in general in pyrazole and isoxazole syntheses. Thus, in the related case of β -substituted enones, the treatment with hydroxylamine under carefully controlled conditions has been reported to afford regioselectively the isomeric 3,5-disubstituted isoxazoles through pH control of the more nucleophilic center in hydroxylamine.^{10a)} Also, a regioselective synthesis of 3,5-disubstituted



Scheme 1.

isoxazoles based on the reactivity of 3-methylthio-2-buten-1-ones has been recently reported.^{10b)}

We herein report on: i) The synthesis of several new hydrazones **3**, their cyclization to pyranopyrazolones **5**, and their conversion to pyrazolylpyrazoles **8**; ii) the identification of Oppenheim's "Dehydroacetchlorid" as 4-chloro-3-(1-chlorovinyl)-6-methyl-2*H*-pyran-2-one (**15**) and its regioselective conversion into pyranopyrazolones **5** or **13**; iii) an NMR study of some of these compounds, mainly based on NOE measurements, which allows unambiguous structure assignment between pairs of possible isomers.¹¹⁾

Results and Discussion

Reaction of **1** with hydrazines in methanol yielded the corresponding hydrazones **3a–e** in fair to good yields (Table 1). The configuration of the C=N double bond was not determined. Nevertheless, hydrazones **3a–c** were cyclized to the corresponding pyrano[4,3-*c*]pyrazol-4(1*H*)-ones **5a–c** (Table 2), although the very insoluble hydrazones **3d–e** could not be cyclized, due to the very low nucleophilicity of the aryl-bound nitrogen atom.

Formation of pyrazolylpyrazole **8c** upon treatment of hydrazone **3c** with aqueous HCl in DME under reflux has precedent in the known^{3a)} formation of **8b**, together with **5b**, when **1** is reacted with two equivalents of phenylhydrazine hydrochloride. Thus, a possible mechanism through **6c** can be envisaged (Scheme 2, path b). However, we have been unable to find the 3,4'-bipyrazoles **16**. (Scheme 2, path a). Therefore, an alternative mechanism through pyrazolone **7c** cannot

be excluded, since its formation from **6c** involves a simple retro-Claisen condensation and the closely related compound **7b** (Ar=C₆H₅) is known¹³⁾ to yield **8b** upon heating.

In the present work, reaction of **1** with two equivalents of either methylhydrazine or (2-hydroxyethyl)hydrazine also gave the corresponding pyrazolylpyrazoles **8a** and **8f** (Table 3).

NMR experiments, summarized below, showed convincingly, that the product from the first reaction of Table 3 was indeed **8a**, rather than **16a**. The 80 MHz ¹H NMR spectrum of **8a** in CDCl₃ showed the presence of several unresolved long range couplings, which were uncovered by resolution enhancement via gaussian multiplication and zero-filling of the FID prior to Fourier transformation.¹⁴⁾ In this way, the assignments shown in Table 4 were made. Double irradiation experiments, also shown in Table 4, confirmed these assignments.

In order to complete the characterization of **8a**, a homonuclear ¹H{¹H} NOE experiment was performed, using the NOE difference technique.¹⁵⁾ Irradiation of the N₁-methyl at δ 3.51 gave about 1% increase in the signals of the C-methyl groups, a result which rules out constitution **16a**, for which a much more significant (≈15%) increase of the adjacent C-methyl group, at δ 2.06, was expected. The only clear increase from this NOE difference experiment was a 10% enhancement of the 5-hydroxyl proton, at δ 8.5–9.5, thus showing that the conformation of **8a** is *seqcis*, and not *seqtrans* (Scheme 3), possibly due to steric hindrance between both methyl groups in the latter.

A similar conclusion was drawn for compound **8c**,

Table 1. Preparation of Oxime **2** and Substituted Hydrazones **3** of Dehydroacetic Acid^{a)}


Product	X	Molar ratio HXNH ₂ /1	Condition	Yield %	Mp θ _m /°C
2	O	2.1 ^{b)}	R.t., 17 h	76	171–173 ^{d)}
3a	CH ₃ N	1.1 ^{c)}	R.t., 25 h ^{d)}	50 ^{e)}	100–102
3b	C ₆ H ₅ N	1.1 ^{c)}	R.t., 1 h	91	211–212 ^{f)}
3c	4-ClC ₆ H ₄ N	1.1 ^{b)}	R.t., 15 h	95	188–190
3d	4-NO ₂ -C ₆ H ₄ N	1.2 ^{c)}	Refl., 16 h	93	220–223
3e	2,4-(NO ₂) ₂ C ₆ H ₃ N	1.2 ^{c)}	Refl., 21 h	35	228–231

a) A 0.1 M (1 M = 1 mol dm⁻³) solution of **1** in MeOH was used, unless otherwise stated. b) A mixture of HXNH₂·HCl and 10% excess sodium acetate trihydrate was used. c) Free HXNH₂ was used. d) Solvent: DME. e) Pyrazolylpyrazole **8a** was detected in the mother liquor. f) Lit, 171–173 °C (Ref. 6). g) Lit, 211–212 °C (Ref. 12).


Table 2. Cyclization of Hydrazones **3**

Starting material	Reagent	Reaction condition	Product	Yield/%	Mp θ _m /°C
3a	1 equiv 1M HCl	DME, r.t., 23 h	5a	73	152–154
3b	Cat. TsOH	Xylene, reflux, 12 h	5b ^{a, b)}	33	156–157 ^{d)}
3c	1.2 equiv 1M HCl	DME, reflux, 49 h	5c ^{c)}	18	220–222

a) Neither Mitsunobu's reagent (EtO₂CN=NCO₂Et/PPh₃) nor POCl₃ under reflux achieved the desired increase in the yield of **5b** and/or decrease in by-product **9b**. b) Also obtained was a second product, in 30% yield, identified as 3,6-dimethyl-1-phenylpyrano[2,3-*c*]pyrazol-4(1*H*)-one, **9b**, mp 150 °C (lit, 150 °C (Ref. 4)). c) Also obtained was pyrazolylpyrazolone **8c**, mp 272–275 °C, in 17% yield. See text for characterization. d) Lit, 156–157 °C (Ref. 3b).




Scheme 2.



Scheme 3.

in which irradiation of the C₃-methyl protons at δ 2.72 gave no significant increase for any of the *p*-chlorophenyl singlets. The results are summarized in Scheme 4.

(2-Hydroxyethyl)hydrazine-derived pyrazolylpyrazole **8f** could not be structurally assigned by NOE mea-



Scheme 4.

surements. However, the close similarity between its spectra and those of **8a** points to a common structural type for both compounds (See experimental). In particular, the UV spectrum of **8a** shows peaks at 210, 226, and 260 nm, while **8f** shows 207, 226, and 258 nm. Also, the aromatic carbons exhibit very similar chemical shifts in the ¹³C NMR spectra of both compounds.

Identification and Reactions of Oppenheim's "Dehydroacetchlorid": Preparation of 1-Alkyl-3,6-dimethylpyrano[4,3-*c*]pyrazol-4(1*H*)-ones (**5**), and 2-Aryl-3,6-dimethylpyrano[4,3-*c*]pyrazol-4(2*H*)-ones (**13**). As early as 1876, Oppenheim and Precht reported^{9a)} that reaction of **1** with phosphoryl chloride and phosphorus pentachloride gave a compound, C₈H₆O₂Cl₂, mp 101 °C, which they named "Dehydroacetchlorid." We have now found, that reaction of **1** with phosphoryl chloride gives 4-chloro-3-(1-chlorovinyl)-6-methyl-2*H*-pyran-2-one (**15**), mp 100 °C, and therefore we propose this constitution for "Dehydroacetchlorid." Constitution **15** is clear from elemental analysis and spectral data (see Experimental). Furthermore, in 1890 Feist reported^{9b)} that reaction of **15** with phenylhydrazine gave an unidentified compound, mp 203 °C, isomeric with **5b**. We have repeated this reaction and, in our hands, the resulting compound showed mp 209–210 °C. This compound was identical with **13b**, previously obtained by a Russian group^{3c,8)} from reaction of 3-acetyl-4-methoxy-6-methyl-2*H*-pyran-2-one (**12**) with phenylhydrazine. A comparison between the

Table 3. Preparation of Pyrazolylpyrazoles **8**

Starting material	Reagent	Reaction condition	Product	Yield/%	Mp θ_m /°C
1	MeNHNH ₂ (2 equiv)	DME, r.t., 47 h	8a	33	203–204
3c	1M aq HCl (1.2 equiv)	DME, reflux, 49 h	8c ^{a)}	17	272–275
1	HOCH ₂ CH ₂ NHNH ₂ (2.5 equiv)	DME, reflux, 91 h	8f	38	79–82


a) See also Table 2, entry 3.

Table 4. The Assigned 80 MHz ¹H NMR Spectrum of **8a**, 50 mM in CDCl₃^{a)}

Proton	δ /ppm	Mult.	<i>J</i> /Hz	Decouplin and NOE
N ₁ -Me	3.63	q	0.3	
C ₃ -Me	2.01	q	0.3	Note ^{b)}
C ₅ -OH	8.5–9.5	broad	—	Note ^{c)}
N _{1'} -Me	3.51	q	0.3	
C _{3'} -Me	2.06	dq	0.6; 0.3	Note ^{d,e)}
C _{4'} -H	5.78	q	0.6	

a) See Scheme 3 for numbering. b) Upon irradiation at δ 3.63 collapses to a singlet. c) Upon low power presaturation at δ 3.51 under NOE difference conditions, this signal shows a 10% enhancement in its integrated area. d) Collapses to a quartet, *J*=0.3 Hz, when decoupling from C_{4'}-H at δ 5.78. e) Collapses to a doublet, *J*=0.6 Hz, when decoupling from N_{1'}-Me at δ 3.51.

reactions of **1**, **12**, and **15** with hydroxylamine or phenylhydrazine is worth here. Thus, **1** gives only products derived from initial attack on the side-chain carbonyl group, and therefore **1** can be converted into the fused heterocycles **4** and **5**, but not into the isomeric **13** and **14**. However, the increased electrophilicity of C-4 in both **12** and **15** opens up the way to **13** and **14** via



Scheme 5.

initial attack of the nucleophile on the now more reactive C-4. This point was confirmed by reaction of **15** with several arylhydrazines (Scheme 5), which furnished the expected 3,6-dimethyl-2-arylpyrano[4,3-*c*]pyrazol-4(2*H*)-ones (**13**) in fair to good yields (Table 5). Furthermore, reaction of **15** with alkylhydrazines gave the 3,6-dimethyl-1-alkylpyrano[4,3-*c*]pyrazol-4(1*H*)-ones (**5**) (Table 5), i.e., the products also expected from initial attack of the now more nucleophilic, substituted nitrogen of the hydrazine on C-4 of the pyrone ring of **15**.

Distinguishing between 1-Substituted 5 and 2-Substituted Pyranopyrazoles 13: NOE Measurements. Throughout the present work, we felt the need for a quick and reliable method for ascertaining the constitution of new pyranopyrazolones as **5** or **13** in an unambiguous way. Since the new compounds were crystalline solids, X-ray diffraction analysis was one possibility, but we were seeking for a faster, more versatile method. The new 2-D NMR techniques¹⁶⁾ were also out of question, because usually they require large amounts of sample and long measuring times. Hopefully, homonuclear ¹H{¹H} NOE measurements¹⁷⁾ particularly in the useful NOE difference mode,¹⁸⁾ are very helpful for the constitutional assignment of simple fused heterocycles.¹⁵⁾ Thus, in 3,6-dimethylpyrano[4,3-*c*]pyrazol-4(1*H*)-ones (**5**), the group bound to N-1 has

Table 5. Reactions of **15** with Hydrazines, RNHNH₂


R	Equiv hydraz.	Reaction condition	Product	Yield/%	Mp θ_m /°C
H	4.1 ^{a)}	EtOH, reflux, 1.75 h	5g	21	192–194
CH ₃	3.1 ^{b)}	DME, r.t., 20 h	5a	40	152–154
HOCH ₂ CH ₂	3.6 ^{b)}	MeOH, r.t., 40 h	5f	81	144–146
H ₂ NCO	3.2 ^{c)}	EtOH, reflux, 21 h	5g ^{d)}	49	192–194
C ₆ H ₅	4.9 ^{b)}	DME, reflux, 54 h	13b	53	209–210 ^{e)}
4-ClC ₆ H ₄	3.1 ^{c)}	MeOH, reflux, 91 h	13c	83	179–182
4-MeC ₆ H ₄	3.2 ^{c)}	MeOH, reflux, 66 h	13h	58	172–173
2-Pyridyl	3.1 ^{b)}	MeOH, reflux, 39 h	13i	33	154–155
3-CF ₃ -C ₆ H ₄	3.2 ^{b)}	MeOH, reflux, 66 h	13j	76	156–157
4-NO ₂ C ₆ H ₄	3.1 ^{b)}	DME, reflux, 20 h	None ^{e)}		

a) Hydrazine hydrate (98%) was used. b) The substituted hydrazine was used as the free base. c) A mixture of RNHNH₂·HCl and 1.2 equiv NaOAc·3H₂O in MeOH was used. d) A second solid, mp 248–250°C, identified as 1,2-hydrazinedicarboxamide, was also obtained from this reaction. e) Starting materials were recovered unaltered due to the poor nucleophilicity of 4-nitrophenylhydrazine. f) Lit, 210°C (Refs. 3c and 8).

Table 6. Homonuclear NOE Enhancements in Pyrano[4,3-*c*]pyrazol-4(1*H*)-ones **5** and **13**^{a)}

Compound	Irradiated proton		Enhanced proton		η /%
	Numbering	δ /ppm	Numbering	δ /ppm	
5a	N ₁ -Me	3.9	H ₇	6.15	4.4
5c	H _{Ar}	7.6	H ₇	6.3	10.0
5f	H ₇	6.2	N ₁ -CH ₂	4.1	1.7
			C ₆ -Me	2.3	1.0
13b	C ₃ -Me	2.8	H _{Ar}	7.5	5.3
13c	C ₃ -Me	2.8	H _{Ar}	7.5	5.0
13h	H _{Ar}	7.3	C ₃ -Me	2.75	2.5
13i	C ₃ -Me	3.1	None.....		
	H ₇	6.25	C ₆ -Me	2.3	1.6
13j	C ₃ -Me	2.8	H _{Ar}	7.6–7.8	4.8

a) Determined on 10 mM solutions in CDCl₃, using the NOE difference technique.



Scheme 6.

its protons close to H-7, while in the isomeric -4(2*H*)-ones the N-2 bound group is close to the C-3 methyl group. A series of homonuclear $^1\text{H}\{^1\text{H}\}$ NOE difference experiments, summarized in Table 6, confirmed this expectations, and provided clear-cut proof for structures **5** and **13**. One exception was compound **13i**, for which no homonuclear NOE enhancements were found besides the trivial $\text{C}_6\text{-Me}\{\text{H}_7\}$. The lack of NOE on any pyridine proton upon irradiation at the C-3 methyl protons was taken as evidence for conformation *seqtrans*, rather than *seqcis* (Scheme 6).

Finally, proof for constitution **13i** rather than **5i** was obtained by means of the recently reported technique^{19,20} of long range, selective heteronuclear $^{13}\text{C}\{^1\text{H}\}$ NOE measurements. Thus, the assigned ^{13}C NMR spectrum of **13i** is given in Table 7. As shown in Scheme 6, the C-3 methyl protons are close to four quaternary carbons, namely C-3, C-3a, and C-4 of the pyranopyrazole nucleus, as well as, to the C-2' carbon of the pyridine substituent. Therefore, low power preirradiation of the C-3 methyl protons should result in a NOE enhancement of these four quaternary carbons.^{19,20}

As shown in Table 7, this was indeed the case. This result, which proves constitution **13i**, rules out the alternative constitution **5i**, in which the pyridine C-2' carbon atom is too far apart from the C-3 methyl protons to undergo any NOE enhancement.

On the other hand, the doubt between constitutions **5g** or **13g** for the product obtained from reaction of **15**

with unsubstituted hydrazine could not be solved by NOE methods. However, its constitution was unambiguously determined as **5g** by comparison of its UV spectrum (215 nm, $\log \epsilon=4.33$ and 255 nm, $\log \epsilon=3.79$) with those of **5a** (218 nm, $\log \epsilon=4.40$ and 258 nm, $\log \epsilon=4.01$) and **5g** (218 nm, $\log \epsilon=4.38$ and 259 nm, $\log \epsilon=3.80$).

Experimental

General. Mp's have been determined on a Kofler block (Reichert, Wien). UV spectra were run in a Perkin-Elmer 550 instrument. IR spectra were measured on a Perkin-Elmer 1310 instrument. 80 MHz ^1H and 20 MHz ^{13}C NMR spectra were recorded in the FT mode on a Bruker WP80SY instrument. MS were taken under EI (70 eV) using a Hewlett-Packard 5985-B instrument.

General preparation procedures, yields and melting points are given in Tables 1–3 and 5. Separations were carried out by column chromatography on silica gel Merck 7754. Special NMR procedures have been described in detail elsewhere: Gaussian resolution enhancement-zero filling,¹⁴ measurement of $^1\text{H}\{^1\text{H}\}$ NOEs by the NOE difference technique,¹⁵ assignment of carbon spectra by selective proton decoupling¹⁹ and measurement of long range, selective heteronuclear NOE enhancements.²⁰

Dehydroacetic Acid Oxime (2). Prepared according to the described procedure.⁶ IR (KBr) 3400–2500, 1660 cm^{-1} ; ^1H NMR (d_6 -DMSO) $\delta=2.15$ (3H, s), 2.35 (3H, s), 4.7–6.2 (1H, broad absorption), 6.05 (1H, s); ^{13}C NMR (d_6 -DMSO) $\delta=13.3$, 19.2, 95.1, 102.0, 158.7, 161.9, 163.0, 173.4; MS m/z (%) 183 (M^+ , 44), 166 (33), 139 (21), 126 (38), 85 (36), 69 (33), 67 (35), 43 (100).

Preparation of Substituted Dehydroacetic Acid Hydrazones 3. The reaction conditions are summarized in Table 1.

Dehydroacetic Acid Methylhydrazone (3a). IR (KBr) 3300, 1690, 1570 cm^{-1} ; ^1H NMR (CDCl_3) $\delta=2.2$ (3H, s), 2.7 (3H, s), 2.8 (3H, s), 5.7 (1H, s); ^{13}C NMR (CDCl_3) $\delta=15.9$, 19.5, 38.3, 94.8, 106.6, 162.2, 163.6, 172.2, 182.8; MS m/z (%) 196 (M^+ , 35), 181 (18), 154 (22), 139 (100), 111 (25), 85 (38), 69 (40), 43 (82). This compound did not give a correct elemen-

Table 7. The Assigned 20 MHz ^{13}C NMR Spectrum of 3,6-Dimethyl-2-(2-pyridyl)pyrano[4,3-*c*]pyrazol-4(2*H*)-one (**13i**) in CDCl_3

Carbon	$\delta_{\text{C}}/\text{ppm}$	Selective decoupling ^{a)}		Selective heteronuclear NOE ^{b)}	
		Irradn. at $\delta_{\text{H}}/\text{ppm}$	Collapses to a singlet	Presatn. at $\delta_{\text{H}}/\text{ppm}$	$\eta/\%$
C3-Me	13.5	3.1	Yes		
C6-Me	19.8	2.3	Yes		
C7	96.5	6.3	Yes		
C3a	106.6	—	—	3.1	+24
C5'	117.3	7.35	Yes		
C3'	122.6	7.85	Yes		
C4'	138.5	7.85	Yes		
C3	145.3	—	—	3.1	+66
C6'	147.7	8.50	Yes		
C7a	150.6	6.3	Yes		
C2'	152.5	—	—	3.1	+11
C6	157.6	2.3	Yes		
C4	159.9	—	—	3.1	+16

a) CW irradiation, decoupling power DP=18H (i.e., 18dB attenuation below nominal 10W). b) CW presaturation, decoupling power DP=55L (i.e., $\gamma\text{B}_2 \approx 2.5$ Hz) for 25s.

tal analysis.

Dehydroacetic Acid Phenylhydrazone (3b).¹² ¹H NMR (*d*₆-DMSO): δ =2.05 (3H, s), 2.5 (3H, s), 5.9 (1H, s), 6.8–7.05 (3H, m), 7.1–7.5 (2H, m), 9.05 (1H, s).

Dehydroacetic Acid (4-Chlorophenyl)hydrazone (3c). IR (KBr) 3300, 1680, 1590 cm⁻¹; ¹H NMR (CDCl₃+CF₃COOH) δ =2.4 (3H, s), 3.0 (3H, s), 6.4 (1H, s), 6.8, 6.9, 7.3, 7.4 (4H, AB system); ¹³C NMR (CDCl₃+CF₃COOH) δ =18.3, 19.6, 94.6, 104.4, 115.8, 129.5, 130.1, 141.5, 165.9, 168.8, 175.1, 180.5; MS *m/z* (%) 294 (20), 292 (M⁺, 58), 237 (86), 235 (80), 125 (41), 99 (53), 85 (60), 43 (100); Found: C, 57.64; H, 3.99; N, 9.53%. Calcd for C₁₄H₁₃ClN₂O₃: C, 57.45; H, 4.48; N, 9.57%.

Dehydroacetic Acid (4-Nitrophenyl)hydrazone (3d). IR (KBr) 3180, 1670, 1590 cm⁻¹; ¹H NMR (CDCl₃+CF₃COOH) δ =2.5 (3H, s), 3.1 (3H, s), 6.4 (1H, s), 7.1, 7.2, 8.4, 8.5 (4H, AB system); ¹³C NMR (CDCl₃+CF₃COOH) δ =17.2, 19.5, 95.7, 105.3, 107.6, 121.8, 142.1, 149.4, 165.5, 166.4, 174.7, 181.8; MS *m/z* (%) 303 (M⁺, 86), 261 (42), 246 (100), 85 (61), 43 (80); Found: C, 55.48; H, 4.23; N, 13.73%. Calcd for C₁₄H₁₃N₃O₅: C, 55.45; H, 4.32; N, 13.86%.

Dehydroacetic Acid (2,4-Dinitrophenyl)hydrazone (3e). IR (KBr) 3300, 1720, 1700, 1570 cm⁻¹; ¹H NMR (CDCl₃) δ =2.3 (3H, s), 2.7 (3H, s), 6.0 (1H, s), 7.4 (1H, d, *J*=14 Hz), 8.4 (1H, dd, *J*=14 Hz, *J'*=3 Hz), 9.2 (1H, d, *J*=3 Hz), 11.3 (1H, s), 14.7 (1H, s); ¹³C NMR (CDCl₃+CF₃COOH) δ =17.7, 19.4, 96.7, 105.4, 115.0, 121.9, 131.6, 132.4, 140.6, 145.2, 166.8, 168.8, 177.0, 182.3; MS *m/z* (%) 348 (M⁺, 36), 306 (20), 291 (28), 256 (26), 151 (43), 109 (44), 85 (54), 67 (90), 43 (100); Found: C, 48.52; H, 3.35; N, 15.93%. Calcd for C₁₄H₁₂N₄O₇: C, 48.28; H, 3.47; N, 16.09%.

Preparation of Pyrano[4,3-*c*]pyrazol-4(1H)-ones (5). The reaction conditions are summarized in Table 2.

1,3,6-Trimethylpyrano[4,3-*c*]pyrazol-4(1H)-one (5a). UV (EtOH) 218 (log ϵ =4.40), 258 (log ϵ =4.01) nm; IR (KBr) 3090, 1720 cm⁻¹; ¹H NMR (CDCl₃) δ =2.3 (3H, s), 2.5 (3H, s), 3.8 (3H, s), 6.1 (1H, s); ¹³C NMR (CDCl₃) δ =12.4, 19.9, 35.4, 91.8, 103.4, 145.2, 148.7, 158.6, 159.1; MS *m/z* (%) 178 (M⁺, 67), 163 (100), 43 (26); Found: C, 60.67; H, 5.62; N, 15.58%. Calcd for C₉H₁₀N₂O₂: C, 60.67; H, 5.66; N, 15.72%.

3,6-Dimethyl-1-phenylpyrano[4,3-*c*]pyrazol-4(1H)-one (5b).^{3b} IR (KBr) 3070, 2950, 1725, 1620, 1590, 1500, 1325, 945, 760 cm⁻¹; ¹H NMR (CDCl₃) δ =2.2 (3H, s), 2.55 (3H, s), 6.3 (1H, s), 7.3 (5H, s); ¹³C NMR (CDCl₃) δ =12.6, 20.1, 92.9, 105.0, 123.2, 128.0, 129.5, 138.4, 144.7, 150.2, 158.8, 160.0; MS *m/z* (%) 240 (M⁺, 100), 239 (9), 226 (11), 225 (73), 77 (15), 51 (10), 43 (22).

1-(4-Chlorophenyl)-3,6-dimethylpyrano[4,3-*c*]pyrazol-4(1H)-one (5c). IR (KBr) 3050, 1740 cm⁻¹; ¹H NMR (CDCl₃+CF₃COOH) δ =2.4 (3H, s), 2.7 (3H, s), 6.4 (1H, s), 7.4, 7.5, 7.6, 7.7 (4H, AB system); ¹³C NMR (CDCl₃+CF₃COOH) δ =11.4, 19.7, 93.2, 104.9, 126.1, 130.7, 133.6, 137.3, 147.0, 152.0, 161.6, 164.3; MS *m/z* (%) 276 (34), 274 (M⁺, 100), 261 (29), 259 (86), 75 (27), 43 (53); Found: C, 60.86; H, 3.88; N, 10.64%. Calcd for C₁₄H₁₁ClN₂O₂: C, 61.31; H, 4.01; N, 10.22%.

1-(4-Hydroxyethyl)-3,6-dimethylpyrano[4,3-*c*]pyrazol-4(1H)-one (5f). UV (EtOH) 218 (log ϵ =4.38), 259 (log ϵ =3.80) nm; IR (KBr) 3360, 1710, 1080, 1030 cm⁻¹; ¹H NMR (CDCl₃) δ =2.3 (3H, s), 2.5 (3H, s), 3.1 (1H, br), 4.0–4.2 (4H, m), 6.3 (1H, s); ¹³C NMR (CDCl₃) δ =12.4, 19.9, 51.3, 60.9, 92.5, 103.3, 146.0, 149.2, 159.0, 159.1; MS *m/z* (%) 209 (M⁺, 100), 177 (60), 164 (39), 43 (47).

3,6-Dimethylpyrano[4,3-*c*]pyrazol-4(1H)-one (5g). Prepared following the conditions described in Table 5. UV

(EtOH) 215 (log ϵ =4.33), 255 (log ϵ =3.79) nm; IR (KBr) 3180, 3120, 1690 cm⁻¹; ¹H NMR (CDCl₃+CF₃COOH) δ =2.4 (3H, s), 2.9 (3H, s), 6.7 (1H, s); ¹³C NMR (CDCl₃+CF₃COOH) δ =11.2, 20.5, 93.7, 105.1, 147.0, 149.0, 159.3, 165.7; MS *m/z* (%) 164 (M⁺, 80), 149 (100), 43 (14); Found: C, 58.26; H, 4.52; N, 17.22%. Calcd for C₈H₈N₂O₂: C, 58.53; H, 4.91; N, 17.06%.

Preparation of 5-Hydroxy-3-methyl-4-(3-methyl-1H-pyrazol-5-yl)-1H-pyrazoles (8). The reaction conditions are summarized in Table 3.

1,3-Dimethyl-5-hydroxy-4-(1,3-dimethyl-1H-pyrazol-5-yl)-1H-pyrazole (8a). IR (KBr) 2920 cm⁻¹; ¹H NMR (CDCl₃) δ =2.0 (2H, s), 2.1 (3H, s), 3.5 (3H, s), 3.7 (3H, s), 5.8 (1H, s); ¹³C NMR (CDCl₃) δ =11.2, 13.0, 30.7, 36.3, 93.6, 106.3, 135.3, 144.2, 147.1, 157.7; MS *m/z* (%) 206 (M⁺, 100), 135 (42), 65 (20), 43 (33); Found: C, 58.05; H, 6.96; N, 27.09%. Calcd for C₁₀H₁₄N₄O: C, 58.24; H, 6.84; N, 27.16%.

1-(4-Chlorophenyl)-5-hydroxy-3-methyl-4-[1-(4-chlorophenyl)-3-methyl-1H-pyrazol-5-yl]-1H-pyrazole (8c). IR (KBr) 3450, 1610 cm⁻¹; ¹H NMR (CDCl₃+CF₃COOH) δ =2.3 (3H, s), 2.6 (3H, s), 6.8 (1H, s), 7.2–7.6 (8H); ¹³C NMR (CDCl₃+CF₃COOH) δ =10.6, 93.2, 111.8, 125.8, 126.9, 130.4, 130.5, 131.1, 131.6, 137.6, 139.1, 139.5, 148.2, 149.0, 157.6; MS *m/z* (%) 402 (12), 400 (62), 398 (M⁺, 96), 231 (24), 113 (100), 111 (34), 75 (32); Found: C, 60.26; H, 4.04; N, 13.81%. Calcd for C₂₀H₁₆Cl₂N₄O: C, 60.30; H, 4.02; N, 14.17%.

5-Hydroxy-1-(2-hydroxyethyl)-3-methyl-4-[3-methyl-1-(2-hydroxyethyl)-1H-pyrazol-5-yl]-1H-pyrazole (8f). IR (KBr) 3280, 2940 cm⁻¹; ¹H NMR (D₂O) δ =2.1 (3H, s), 2.2 (3H, s), 3.8 (4H), 4.0 (4H), 6.1 (1H, s); ¹³C NMR (D₂O) δ =11.1, 13.2, 47.0, 51.6, 60.2, 61.3, 95.7, 108.0, 136.5, 146.7, 150.0, 161.6; MS *m/z* (%) 266 (M⁺, 100), 235 (74), 223 (20), 178 (29); No correct elemental analysis for this compound was achieved.

3,6-Dimethyl-1-phenylpyrano[2,3-*c*]pyrazol-4(1H)-one (9b).⁴ This compound was obtained as by-product in the cyclization reaction of **3b** to **5b**. ¹H NMR (CDCl₃) δ =2.4 (3H, s), 2.6 (3H, s), 6.0 (1H, s), 7.3–7.9 (5H, s); ¹³C NMR (CDCl₃) δ =13.7, 19.2, 106.7, 112.4, 120.8, 127.1, 129.2, 137.1, 146.5, 153.5, 161.4, 175.4; MS *m/z* (%) 240 (M⁺, 100), 200 (70), 132 (20), 91 (58), 77 (15), 51 (10).

3,6-Dimethylpyrano[4,3-*c*]pyrazol-4(2H)-ones (13). The reaction conditions are summarized in Table 5.

3,6-Dimethyl-2-phenylpyrano[4,3-*c*]pyrazol-4(2H)-one (13b).^{3c,8} IR (KBr) 3070, 2900, 1715, 1635, 1580, 1270, 1220, 1150, 1080, 1040, 960 cm⁻¹; ¹H NMR (CDCl₃) δ =2.2 (3H, s), 2.6 (3H, s), 6.25 (1H, s), 7.45 (5H, s); ¹³C NMR (CDCl₃) δ =11.8, 19.9, 96.7, 105.8, 125.3, 129.0, 129.3, 138.6, 143.2, 151.0, 157.4, 160.1; MS *m/z* (%) 240 (M⁺, 100), 239 (28), 225 (83), 77 (55), 51 (21), 43 (26).

2-(4-Chlorophenyl)-3,6-dimethylpyrano[4,3-*c*]pyrazol-4(2H)-one (13c). IR (KBr) 3100, 1760 cm⁻¹; ¹H NMR (CDCl₃+CF₃COOH) δ =2.4 (3H, s), 2.7 (3H, s), 6.7 (1H, s), 7.3, 7.4, 7.6, 7.7 (4H, AB system); ¹³C NMR (CDCl₃+CF₃COOH) δ =11.3, 19.6, 95.2, 105.3, 127.4, 130.7, 133.1, 138.5, 147.8, 150.2, 161.6, 163.0; MS *m/z* (%) 276 (34), 274 (M⁺, 100), 261 (27), 259 (82), 152 (23), 111 (45), 75 (53), 43 (78); Found: C, 61.21; H, 3.88; N, 10.06%. Calcd for C₁₄H₁₁ClN₂O₂: C, 61.31; H, 4.01; N, 10.22%.

3,6-Dimethyl-2-(4-methylphenyl)pyrano[4,3-*c*]pyrazol-4(2H)-one (13h). IR (KBr) 3100, 1725 cm⁻¹; ¹H NMR (CDCl₃) δ =2.3 (3H, d, *J*=1.5 Hz), 2.4 (3H, s), 2.6 (3H, s), 6.3 (1H, q, *J*=1.5 Hz), 7.3 (4H, s); ¹³C NMR (CDCl₃) δ =11.8, 19.8, 21.0, 96.7, 106.0, 125.1, 129.8, 138.1, 139.1, 143.1, 150.8, 157.2, 160.0; MS *m/z* (%) 254 (M⁺, 100), 239 (93), 132 (10), 91

(32); Found: C, 70.58; H, 5.33; N, 10.85%. Calcd for $C_{15}H_{14}N_2O_2$: C, 70.85; H, 5.55; N, 11.02%.

3,6-Dimethyl-2-(2-pyridyl)pyrano[4,3-*c*]pyrazol-4(2*H*)-one (13i). IR (KBr) 3080, 1720 cm^{-1} ; 1H NMR ($CDCl_3$) δ =2.3 (3H, s), 3.1 (3H, s), 6.3 (1H, s), 7.3 (1H, m), 7.8–7.9 (2H, m), 8.5 (1H, m); ^{13}C NMR ($CDCl_3$) δ =13.5, 19.8, 96.5, 106.6, 117.3, 122.6, 138.5, 145.3, 147.7, 150.6, 152.5, 157.6, 159.9; MS m/z (%) 241 (M^+ , 95), 226 (100), 198 (38), 170 (33), 78 (77); Found: C, 64.60; H, 4.29; N, 17.47%. Calcd for $C_{13}H_{11}N_3O_2$: C, 64.72; H, 4.60; N, 17.42%.

3,6-Dimethyl-2-(3-trifluoromethylphenyl)pyrano[4,3-*c*]pyrazol-4(2*H*)-one (13j). IR (KBr) 3100, 1730 cm^{-1} ; 1H NMR ($CDCl_3$) δ =2.3 (3H, d, J =1.7 Hz), 2.6 (3H, s), 6.3 (1H, q, J =1.7 Hz), 7.7 (4H, m); ^{13}C NMR ($CDCl_3$) δ =11.8, 19.8, 96.5, 106.2, 122.3 (q, J =4 Hz), 124.0 (q, J =273 Hz), 125.5 (q, J =4 Hz), 128.2, 130.0, 131.7 (q, J =33 Hz), 139.0, 143.5, 151.3, 157.8, 159.7; MS m/z (%) 308 (M^+ , 100), 293 (89), 216 (26), 186 (32), 161 (37), 145 (79), 141 (26), 63 (52), 43 (97); Found: C, 58.39; H, 3.48; N, 9.05%. Calcd for $C_{15}H_{11}F_3N_2O_2$: C, 58.45; H, 3.60; N, 9.09%.

4-Chloro-3-(1-chlorovinyl)-6-methyl-2*H*-pyran-2-one (15). A solution of **1** (4.02 g, 24 mmol) in 30 ml of phosphoryl chloride was refluxed for 4.5 h. The cooled mixture was poured very slowly and with stirring over 200 g of ice. This water solution was extracted with chloroform and the organic phase was washed with sodium hydrogenocarbonate. This extract was dried over magnesium sulfate and removal of the solvent left 3.6 g of a black residue. This crude was purified by sublimation at 85 °C/0.2 mmHg (1 mmHg=133.322Pa) affording 1.827 g (33% yield) of a white solid identified as **15**: Mp 100 °C (lit: 101 °C (Ref. 9a)); IR (KBr) 3070, 1700 cm^{-1} ; 1H NMR ($CDCl_3$) δ =2.2 (3H, s), 5.55 (1H, d, J =2 Hz), 5.85 (1H, d, J =2 Hz), 6.2 (1H, s); ^{13}C NMR ($CDCl_3$) δ =19.6, 106.5, 121.0, 121.2, 130.0, 149.5, 158.9, 162.1; MS m/z (%) 208 (5), 206 (32), 204 (M^+ , 46), 178 (20), 176 (33), 171 (24), 169 (72), 143 (32), 141 (100), 137 (3), 135 (21), 133 (33), 77 (25), 63 (53), 43 (47); Found: C, 46.65; H, 2.98%. Calcd for $C_8H_6Cl_2O_2$: C, 46.87; H, 2.95%.

Financial support from "Comisión Asesora de Investigación Científica y Técnica" through project No. 2014/83 and a generous gift of dehydroacetic acid from LONZA A.G. (Basel) are gratefully acknowledged. We also thank generous funding from "Fundación María Francisca de Roviralta", which allowed the purchase of the NMR spectrometer and "Direcció General d'Ensenyament Universitari", Generalitat de Catalunya, for the NMR data system.

References

- 1) For recent examples involving dehydroacetic acid derivatives or coumarins see: a) B. Chantegrel and S. Gelin, *Synthesis*, **1985**, 548; b) B. Chantegrel, A. I. Nadi, and S. Gelin, *J. Heterocycl. Chem.*, **21**, 17 (1984); c) B. Chantegrel, A. I. Nadi, and S. Gelin, *J. Org. Chem.*, **49**, 4419 (1984); d) S. Gelin, B. Chantegrel, and C. Deshayes, *J. Heterocycl. Chem.*, **19**, 989 (1982); e) D. S. Rao, M. C. Ganorkar, C. S. Reddy, and V. T. John, *Curr. Sci.*, **49**, 511 (1980); f) R. Motokuni, M. Tanaka, S. Hashimoto, and T. Suzue, Jpn. Patent 7778895 (*Chem. Abstr.*, **87**, 168029m (1977)); g) A. S. Shawali, B. E. Elanadoul, and H. A. Albar, *Tetrahedron*, **41**, 1877 (1985); h) B. Chantegrel, A. Nadi, and S. Gelin, *Synthesis*, **1983**, 214; i) B. Chantegrel, A. Nadi, and S. Gelin, *Tetrahedron Lett.*, **24**, 38 (1983).
- 2) a) G. Minunni, *Gazz. Chim. Ital.*, **29II**, 456 (1899); b) E. Marcus, J. K. Chan, and J. L. Hughes, *J. Chem. Eng. Data*, **12**, 151 (1967).
- 3) a) R. Stollé, *Ber.*, **38**, 3023 (1905); b) E. Benary, *Ber.*, **43**, 1070 (1910); c) A. A. Akhrem, A. M. Moiseenkov, F. A. Lakhvich, and S. P. Smul'skii, *Izv. Akad. Nauk SSSR, Ser. Khim.*, **1971**, 1098.
- 4) S. Gelin, B. Chantegrel, and A. I. Nadi, *J. Org. Chem.*, **48**, 4078 (1983).
- 5) R. von Rothenburg, *Ber.*, **27**, 790 (1894).
- 6) A. Inoue and S. Iguchi, *Chem. Pharm. Bull.*, **12**, 381 (1964).
- 7) V. K. Makesh and R. S. Gupta, *Indian J. Chem.*, **12**, 570 (1974).
- 8) A. A. Akhrem, A. M. Moiseenkov, F. A. Lakhvich, V. I. Kadentsev, and O. S. Chizhov, *Izv. Akad. Nauk SSSR, Ser. Khim.*, **1970**, 1206.
- 9) a) A. Oppenheim and H. Precht, *Ber.*, **9**, 1099 (1876); b) F. Feist, *Liebigs Ann. Chem. Pharm.*, **257**, 253 (1890); c) F. Feist, *Ber.*, **25**, 335 (1892).
- 10) a) C. Kashima, N. Yoshiwara, S. Shirai, and Y. Omote, *Chem. Lett.*, **1982**, 1455; b) M. Yokoyama, K. Tsuji, and M. Kushida, *J. Chem. Soc., Perkin Trans. 1*, **1986**, 67.
- 11) Preliminary communication: A. Cantos, P. de March, M. Moreno-Mañas, A. Pla, F. Sánchez-Ferrando, and A. Virgili, *Chem. Lett.*, **1986**, 295.
- 12) W. H. Perkin, Jr. and C. Bernhart, *Ber.*, **17**, 1522 (1884).
- 13) V. Jonescu and V. Georgescu, *Bull. Soc. Chim. Fr.*, **41**, 1515 (1927).
- 14) P. de March and F. Sánchez-Ferrando, *Afinidad*, in the press.
- 15) M. R. Cuberes, M. Moreno-Mañas, and F. Sánchez-Ferrando, *Magn. Reson. Chem.*, **23**, 814 (1985).
- 16) A. Bax, "Two-Dimensional Nuclear Magnetic Resonance in Liquids," Delft University Press, Dordrecht, Holland (1982).
- 17) J. H. Noggle and R. E. Schirmer, "The Nuclear Overhauser Effect. Chemical Applications," Academic Press, New York (1971).
- 18) J. K. M. Sanders and J. D. Mersh, *Progress Nucl. Magn. Reson. Spectroscopy*, **15**, 353 (1982).
- 19) F. Sánchez-Ferrando, *Magn. Reson. Chem.*, **23**, 185 (1985).
- 20) C. Cativiela and F. Sánchez-Ferrando, *Magn. Reson. Chem.*, **23**, 1072 (1985).